NAM
CERO

Nexpoint Asset Management’s CERo Therapeutics CERO Stock Holding History

Nexpoint Asset Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-109
Closed -$2.24M – 111
2022
Q4 		$2.24M Hold
109
– – 0.17% 49
2022
Q3 		$2.2M Hold
109
– – 0.15% 67
2022
Q2 		$2.18M Hold
109
– – 0.19% 57
2022
Q1 		$2.18M Hold
109
– – 0.28% 51
2021
Q4 		$2.15M Buy
+109
New +$2.16M 0.3% 58

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Nexpoint Asset Management's CERO Position: Q1 2023 in Review

Nexpoint Asset Management sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 109 shares — an estimated $2.24M sold.

Nexpoint Asset Management first reported a position in CERO in Q4 2021 and held it in 5 quarters. The position peaked at $2.24M in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • Nexpoint Asset Management reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Nexpoint Asset Management sold 109 CERo Therapeutics shares in Q1 2023, an estimated $2.24M.
  • Nexpoint Asset Management first reported a position in CERo Therapeutics in Q4 2021 and held it in 5 quarters.
  • Nexpoint Asset Management's CERo Therapeutics position peaked at $2.24M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on Nexpoint Asset Management's 13F filing for Q1 2023, filed 15 May 2023.